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We evaluated whether four recombinant antigens previously used for vaccination against experimental
infection with Leishmania (Leishmania) major could also induce protective immunity against a challenge with
Leishmania (Viannia) braziliensis, the species responsible for 90% of the 28,712 annual cases of cutaneous and
mucocutaneous leishmaniasis recorded in Brazil during the year of 2004. Initially, we isolated the homolog
genes encoding four L. (V.) braziliensis antigens: (i) homologue of receptor for activated C kinase, (ii)
thiol-specific antioxidant, (iii) Leishmania elongation and initiation factor, and (iv) L. (L.) major stress-
inducible protein 1. At the deduced amino acid level, all four open reading frames had a high degree of identity
with the previously described genes of L. (L.) major being expressed on promastigotes and amastigotes of L.
(V.) braziliensis. These genes were inserted into the vector pcDNA3 or expressed as bacterial recombinant
proteins. After immunization with recombinant plasmids or proteins, BALB/c mice generated specific antibody
or cell-mediated immune responses (gamma interferon production). After an intradermal challenge with L.
(V.) braziliensis infective promastigotes, no significant reduction on the lesions was detected. We conclude that
the protective immunity afforded by these four vaccine candidates against experimental cutaneous leishman-
iasis caused by L. (L.) major could not be reproduced against a challenge with L. (V.) braziliensis. Although
negative, we consider our results important since they suggest that studies aimed at the development of an
effective vaccine against L. (V.) braziliensis, the main causative agent of cutaneous leishmaniasis in the New
World, should be redirected toward distinct antigens or different vaccination strategies.
The protozoan parasite Leishmania (Viannia) braziliensis
commonly causes localized cutaneous leishmaniasis (CL);
however, a chronic mucosal leishmaniasis (ML) may de-
velop in some infected individuals, with severe and progres-
sive manifestations (reviewed in reference 11). At present,
this species accounts for more than 90% of the 28,712 an-
nual cases of CL and ML recorded in Brazil in 2004 (7).
Although chemotherapies for CL and ML do exist, there are
several limitations: (i) drug treatment is rarely affordable by
those who need them, (ii) drug treatment requires daily
injections of the drug for weeks, (iii) drug treatment can be
associated with side effects, and (iv) drug resistance is be-
coming an increasing problem (13, 24; reviewed in refer-
ences 3 and 32). To make matters worse, control of CL and
ML is problematic due to the sylvatic nature of both vectors
and reservoirs, making insecticide spraying and the elimina-
tion of reservoirs particularly difficult (26). Due to these
difficulties, in the long run, the development of an effective
vaccine may help both the prevention and the treatment of
CL and ML caused by L. (V.) braziliensis.
Most studies conducted thus far in vaccination against CL
used genes and/or antigens isolated and characterized from
Leishmania (Leishmania) major or L. (L.) amazonensis (8, 31;
reviewed in references 9 and 21). Among the leading candi-
dates to the development of a vaccine against CL, there are
homologues of the receptor for activated C kinase protein
(LACK or p36), Leishmania elongation and initiation factor
(LeIF), L. (L.) major stress inducible protein 1 (LmSTI1), and
thiol-specific antioxidant (TSA) from L. (L.) major (5, 6, 10,
14, 15, 28, and 30).
Based on these promising prospects, the present study was
designed to test whether four recombinant antigens previously
used for vaccination against experimental infection with L. (L.)
major (LACK, LmSTI1, LeIF, and TSA) could also generate
protective immunity against an intradermal (i.d.) challenge
with L. (V.) braziliensis. We considered this question very im-
portant because, as mentioned above, this species is responsi-
ble for most cases of CL and ML in Brazil and in the New
World.
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MATERIALS AND METHODS
Parasites and mice. L. (V.) braziliensis (MHOM/BR/1975/M2903 and MHOM/
BR/01/BA788) and L. (L.) major (Friedlin strain) promastigotes were grown at
26°C in 199 medium (Life Technologies) supplemented with 40 mM HEPES, 0.1
mM adenine, 2 mM L-glutamine, 5 mg of hemin/ml (in 50% triethanolamine),
100 U of penicillin/ml, 100 mg of streptomycin/ml, and 10% heat-inactivated fetal
bovine serum (all from Life Technologies). To L. (V.) braziliensis promastigote
culture was added 2% of sterile human male urine. The parasites were isolated
from stationary phase in culture (5 to 6 days old). L. (V.) braziliensis amastigotes
were obtained from infected mouse bone marrow-derived macrophage culture
(1). Amastigote suspensions of L. (V.) braziliensis were prepared by disruption of
infected macrophages scraped from the flask 48 h after infection with promas-
tigotes. These cells were ruptured through a 22-gauge needle and were centri-
fuged at 250  g for 10 min; the resulting supernatant was centrifuged at
1,400  g for 10 min, and the pellet was resuspended in RPMI. The suspension
was kept under agitation for 4 h at room temperature and centrifuged at 250 
g for 10 min. The final pellet contained purified amastigotes that were essentially
free of contamination by other cells (2).
BALB/c mice were obtained from the Universidade de Sa˜o Paulo, Sa˜o Paulo,
Brazil. The mice were maintained under pathogen-free conditions and used at 6
to 8 weeks of age. The protocols for the experiments with mice were approved by
the Committee of Ethics of the Federal University of Sa˜o Paulo–Escola Paulista
de Medicina.
Genomic DNA isolation, PCR amplification, DNA cloning, and sequencing.
Genomic DNA from promastigote forms of L. (V.) braziliensis was extracted
essentially as described previously (4). Amplification of the open reading frames
(ORFs) of the antigens from L. (V.) braziliensis was carried out with specific
primers designed according to the sequences available at GenBank. Briefly, for
PCR we used 500 ng of L. (V.) braziliensis genomic DNA, 200 pmol of each
primer, 10 mM deoxynucleoside triphosphate mix, 3 mM MgCl2, and Platinum
Taq DNA polymerase (Gibco-BRL) in a final volume of 50 l. The reaction was
performed for a first step of 5 min at 94°C and 35 cycles, with the following
thermal profile: 30 s at 94°C, 30 s at 50°C, and 1 to 2 min at 68°C, with a final step
of 7 min at 4°C. PCR products were placed on to a 1% agarose gel and excised
from it, and the DNA was purified with GeneClean II kit (Bio 101). The products
were cloned into the pMOSBlue vector (Amersham-Pharmacia). The recombi-
nant clones selected were sequenced.
Automatic sequencing of double-stranded DNA was performed by using the
BigDye terminator cycle sequencing kit (Perkin-Elmer) on an ABI Prism 377
sequencer (Perkin-Elmer). DNA and predicted amino acid sequences were an-
alyzed by using the DNASTAR package version 5.00 (DNASTAR, Inc.). Align-
ments were produced by using the CLUSTAL W program.
For a bacterial expression vector, we used the pHIS, plasmid kindly provided
by Peter Sheffield (University of Virginia) (27). The ORFs of the genes contain-
ing the described restriction site sequences, for directional cloning, were re-
moved from pMOSBlue vector by treatment with the specific restriction enzymes
and linked into the pHIS vector treated with the same enzymes. For eukaryotic
expression the commercially available plasmid pcDNA3 (Invitrogen, San Diego,
CA) was used as the mammalian expression vector. The recombinant plasmids
were obtained as described above using the ORFs of the genes containing the
antigens. Immunization plasmids were obtained by inserting the nucleotide se-
quence encoding the mouse immunoglobulin  chain signal peptide (IgSP) in
frame with the 5 nucleotide sequence of the genes. The nucleotide sequence
encoding IgSP was generated as described previously (4). The recombinant
plasmids were produced in Escherichia coli DH5 and purified on cesium chlo-
ride density gradients according to standard protocols (25). The DNA concen-
tration was estimated to be 260 nM. Each plasmid DNA was diluted in sterile
phosphate-buffered saline (PBS) to a concentration of 1 mg/ml.
Northern blot analysis. Total RNA was isolated from 108 promastigotes and
amastigotes of L. (V.) braziliensis and promastigotes of L. (L.) major using
TRIzol reagent (Gibco-BRL) according to the manufacturer’s instructions. For
Northern blot analyses, total RNA was resuspended in RNase-free water; equil-
ibrated in a buffer containing formamide, formaldehyde, and morpholinepro-
panesulfonic acid; heated for 30 min at 70°C; and fractioned in 1% agarose
formaldehyde gels (26). An RNA ladder ranging from 0.24 to 9.5 kb was used as
size marker (Life Technologies). Gels were photographed and transferred to
membranes using 20 SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium
citrate), and the RNA was fixed and cross-linked to Hybond-N membranes by
UV irradiation. Filters were prehybridized for 2 h at 42°C in a hybridization
solution containing 50% (vol/vol) formamide (Sigma), 5 SSC, 5 Denhardt
solution, 10 g of tRNA (Sigma) per ml, and 100 g of salmon testes DNA
(Sigma) per ml. Filters were hybridized overnight at the same temperature with
the indicated probes labeled with [-32P]dCTP (Amersham) by using an oligo-
labeling kit (Pharmacia Biotech) according to the manufacturer’s instructions.
The filters were washed in SSC solutions (2 to 0.1) containing 0.1% (wt/vol)
sodium dodecyl sulfate (SDS) from 42 to 50°C and exposed to Hyperfilm (Am-
ersham-Pharmacia) or a Typhoon system (Amersham-Pharmacia).
Expression and purification of the recombinant proteins. The recombinant
plasmids obtained were transformed into E. coli BL21(DE3) host cells (Novagen,
Madison, WI). Protein expressions were performed as described previously (30).
Cells were harvested from 500-ml batch cultures by centrifugation and resus-
pended in 20 ml of binding buffer (0.1 M sodium phosphate [pH 8.0], 10 mM
Tris-HCl [pH 8.0]) containing 2 mM phenylmethylsulfonyl fluoride. E. coli was
lysed by adding 15 mg of lysozyme and rocking for 30 min at 4°C, following
sonication (four times for 30 s each time), and then spun at 12,000 rpm for 30 min
to pellet the cells. Only the TSA protein was obtained as a soluble protein. The
protocol was continued to obtain the insoluble proteins LACK, LeIF, and
LbSTI1. Briefly, the inclusion bodies were washed three times in 1% CHAPS
{3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate} in 10 mM
Tris-HCl (pH 8.0). The samples were spun at 12,000 rpm for 30 min to pellet the
inclusion bodies. These were finally solubilized in 20 ml of binding protein
containing 8 M urea.
All of the recombinant antigens with His tag residues were batch bound to
Ni-nitrilotriacetic acid agarose resin (5 ml per 500-ml induction) by rocking at
room temperature for 1 h, and the complexes were passed over a column. The
flowthrough was passed twice over the same column, and it was washed three
times with 30 ml each of wash buffer (0.1 M sodium phosphate and 10 mM
Tris-HCl [pH 6.3]) also containing 8 M urea. Bound protein was eluted with 30
ml of 100 mM imidazole in wash buffer, and 3-ml fractions were collected. At this
final step the samples were analyzed by SDS-polyacrylamide gel electrophoresis
(PAGE).
Immunizations. To perform the indirect immunofluorescence assay (IIA),
BALB/c mice were injected in the hind footpad (subcutaneously) with 10 g of
each purified recombinant proteins (His6-LACK, His6-TSA, His6-LbSTI, and
His6-LeIF) in Freund complete adjuvant (CFA). After 2 weeks the mice were
injected at a location 1 cm distal to the rump with 10 g of each recombinant
protein with incomplete Freund adjuvant (IFA). Mice were bled with 7 days after
the first dose and 10 days after the last dose. The plasma fraction was obtained
and stored at 20°C.
DNA immunization was performed as described earlier (4), using the recom-
binant DNA plasmids either alone or together. Empty pcDNA3 plasmid was
used as a control. Both tibialis anterioris muscles were injected with 3.5 g of
cardiotoxin (Sigma). Five days later, 50 g of plasmid DNA were injected
intramuscularly at the same sites as for the cardiotoxin injection (a total of 100
g of plasmid DNA per mouse). The subsequent doses consisted of the same
amount of plasmid DNA injected 2 and 4 weeks after the first immunizing dose.
The protocol for immunization with the recombinant proteins was performed
by the intraperitoneal administration of 25 g of each purified protein in the
presence of CpG ODN 1826 (10 g/dose/mouse; Coley Pharmaceuticals, Welle-
sley, MA) and 2% aluminum hydroxide (alum; Superfos Biosector, Denmark),
i.e., 2.5 l/g of recombinant protein. Some animals received all four proteins
together depending on the immunization strategy. The control group received
only CpG ODN 1826 and alum in PBS. Immunizations were performed by the
administration of three doses given 2 weeks apart.
The immunization protocol before the i.d. challenge consisted of two doses of
the recombinant DNA plasmids followed by one or two doses of the purified
recombinant proteins. At 2 weeks after the last dose, mice were challenged with
promastigotes of L. (V.) braziliensis. BALB/c mice were challenged i.d. as de-
scribed previously (20). Briefly, cultured promastigote forms of L. (V.) brazilien-
sis (MHOM/BR/01/BA788) were adjusted to a concentration of 107 parasites/ml
in PBS, and 10 l was injected into the ear dermis of each mouse. The infection
was monitored for 9 to 10 weeks, and lesion formation was measured once a
week with a direct caliper.
IIA. Macrophages (105 cells/coverslip) were infected with stationary promas-
tigotes of L. (V.) braziliensis (at a 10:1 parasite/cell ratio); 48 h later the coverslips
were used in IIA. Promastigotes of L. (V.) braziliensis or infected macrophages
were fixed for 40 min in 3.5% paraformaldehyde–PBS and washed three times
with PBS, and the solution was adjusted to a concentration of 107 parasites per
ml. Portions (10 l) of the parasite suspension were layered onto round, coated
coverslips and allowed to stand overnight at room temperature. Coverslips were
stored at 20°C until use. Slides containing promastigotes or amastigote-infected
macrophages were blocked with PBS containing 2% gelatin and 0.1% NaN3 and
permeabilized with 0.1% saponin (BDH; Amersham, United Kingdom) in 0.2
gelatin and 0.1% NaN3 (PGN) and then incubated with different sera from mice
immunized with recombinant proteins (LACK, TSA, LbSTI, or LeIF) diluted to
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1:100 in PGN for 1 h at room temperature, washed three times with PBS, and
developed with rabbit immunoglobulin G (IgG) Cy3-conjugated anti-mouse IgG
(Sigma Chemical Co., St. Louis, MO) diluted 1:100 in PGN with 10 M DAPI
(4,6-diamidino-2-phenylindole) for an 1 h at room temperature.
Infected macrophages were incubated with a pool of sera from patients with
mucocutaneous leishmaniasis diluted 1:100 for 1 h at room temperature, washed
three times with PBS, and then incubated with goat IgG fluorescein isothiocya-
nate (FITC)-conjugated anti-human IgG (Sigma) diluted 1:50 for 1 h in the
presence of 10 M DAPI. This DNA dye preferentially labels condensed DNA
and clearly demonstrates host cell nucleoli and parasite kinetoplasts. Control
uninfected macrophages cells were subjected to the same procedure. After three
washes with PBS, the coverslip and promastigotes onto coverslips were mounted
in glycerol buffered with 0.1 M Tris (pH 8.6) and 0.1% paraphenylenediamine to
reduce bleaching and observed by using an Optishot-2 fluorescence microscope
(Nikon). Images were acquired on a Bio-Rad 1024-UV confocal system attached
to a Zeiss Axiovert microscope using a 63 N.A. 1.4 Phan-Apochromatic (dif-
ferential interference contrast) oil immersion objective.
Immunoblot. Extracts from L. (V.) braziliensis promastigotes (30 g of protein/
lane) were subjected to SDS–12% PAGE and transferred to nitrocellulose mem-
branes. Membranes were blocked with 5% powdered skim milk in PBS and
incubated for 1 h with sera from BALB/c mice immunized with the recombinant
proteins diluted 1:50. After a washing step with 0.05% Tween 20 in PBS, the
nitrocellulose strips were incubated with peroxidase-conjugated anti-mouse and
then developed with diaminobenzidine and H2O2.
Immunological assays. Enzyme-linked immunosorbent assay (ELISA) was
performed essentially as described earlier (4).
Spleen cells collected from immunized BALB/c mice 2 weeks after the third
immunizing dose were cultured in RPMI medium supplemented with 10 mM
HEPES, 2 mM L-glutamine, 5  105 M 2-mercaptoethanol, 1 mM sodium
pyruvate, 1% (vol/vol) nonessential amino acid solution, and 1% (vol/vol) min-
imal essential medium vitamin solution (all purchased from Life Technologies);
100 U of penicillin and streptomycin (Sigma) per ml; and 10% (vol/vol) of fetal
bovine serum (pH 7.4; HyClone, Logan, UT). The cultures were maintained at
37°C in an atmosphere containing 5% CO2. The concentration of cells was 5 
106 viable cells per ml. The assay was performed in 96-well flat-bottom plates
(Costar); 0.2 ml of cell suspension was pipetted into each well, and the respective
antigens (recombinant proteins) were added at a concentration of 10 g/ml. We
collected supernatants for cytokine determination after 3 days in culture. Each
determination was done in triplicate; the results are reported as means  the
standard deviations (SD). The concentration of gamma interferon (IFN-	) was
estimated by a capture ELISA using commercially available antibody and re-
combinant cytokine (Pharmingen, San Diego, CA) as described previously (23).
The concentration of cytokine in each sample was determined from standard
curves executed in parallel with known concentrations of IFN-	. The detection
limit of the assay was 0.2 ng/ml.
GenBank accession numbers. The GenBank accession numbers for the lack
gene are as follows: AF363978.1, L. (V.) braziliensis; AF034804, L. (L.) major;
AF363974.1, L. (L.) donovani; L. (L.) amazonensis, EU016104; and L. (L.)
chagasi, EU016105. The GenBank accession numbers for the tsa gene are as
follows: AF069386, L. (L.) major; AF312397, L. (L.) chagasi; and AAL25847.1,
L. (L.) donovani. The GenBank accession numbers for the leif gene are as
follows: Q25225, L. (V.) braziliensis; and A81464, L. (L.) major. The GenBank
accession numbers for the sti1 gene are as follows: AAB37318, L. (L.) major; and
AAY88229.1, L. (L.) donovani.
RESULTS
Identification and characterization of the homolog genes
lack, lmsti1, leif, and tsa from L. (V.) braziliensis. The deduced
amino acid sequences of the different genes isolated from L.
(V.) braziliensis were compared to previously described genes
of Leishmania. The deduced amino acid sequence of the lack
ORF was almost identical to the published sequence of L. (V.)
braziliensis, being different in only 11 amino acids, four of them
with conservatives modifications (Table 1). The previously de-
scribed immunodominant T-cell epitope recognized by CD4
T cells from H-2d mice (amino acids 156 to 173) was invariant
(19).
The tsa gene cloned from L. (V.) braziliensis had not been
previously reported. Comparing the complete deduced amino
acid sequence from L. (V.) braziliensis to the L. (L.) major
sequence (35), we observed 83% of identity with 32 amino acid
substitutions, with 17 being conservative (Table 1).
The deduced amino acid sequences of the lbsti1 ORF cloned
from L. (V.) braziliensis had the amino- and the carboxyl-
terminal regions highly conserved compared to the same gene
from L. (L.) major, with only a few substitutions (Table 1) (34,
36). Interestingly, within the region comprising the amino acids
158 to 220 there are several amino acid modifications. In this
region, there are 30 different amino acids, with seven conser-
vative modifications. Also, the loss of two amino acid residues
was observed in the L. (V.) braziliensis sequence (Fig. 1).
The leif gene we cloned from L. (V.) braziliensis displayed
100 or 98% identity with the previously described ORFs from
L. (V.) braziliensis or L. (L.) major, respectively (29). In the
latter case, we found seven amino acid substitutions (five being
conservative) over their entire sequence (Table 1). The de-
duced amino acid sequence retained a series of conserved
TABLE 1. Comparison of the predicted amino acids sequences of the genes lack, lmsti1, leif, and tsa cloned from L. (V.) braziliensis or other
species of Leishmania
Gene
Predicted amino acidsa
L. (V.) braziliensisb L. (L.) major L. (L.) amazonensis L. (L.) chagasi L. (L.) donovani
lack 43, 58, 99, 115, 148,
183, 231, 237,
254, 256, 277
31, 43, 58, 99, 148, 183,
231, 237, 254, 256, 277
43, 58, 99, 148, 183,
231, 237, 254,
256, 277
43, 58, 99, 183, 231, 237,
254, 256, 277, 312
43, 48, 99, 183, 231, 237,
254, 256, 277
tsa NA 8, 14, 18, 32, 56, 58, 63, 64,
70, 74, 75, 78, 91, 99,
101, 111, 113, 115, 120,
122, 123, 136, 138, 144,
152, 181, 182, 188, 189,
191, 192
NA 5, 8, 10, 18, 33, 58, 61, 62,
63, 64, 70, 74, 75, 78,
91, 99, 101, 111, 113,
120, 123, 136, 138, 139,
144, 181, 182, 188, 189,
191, 192
5, 8, 10, 18, 33, 58, 61, 62,
63, 64, 70, 74, 75,78, 91,
99, 101, 111, 113, 120,
123, 136, 138, 139,
144, 181, 182, 188, 189,
191, 192
leif 363 2, 4, 6, 7, 125, 149, 384 NA NA NA
sti1 NA 60, 68, 98, 158–220*, 250,
254, 270, 310, 314, 530
NA NA 61, 69, 100, 106,
158–220*, 251, 271,
287, 310, 312, 316, 379
a The positions of amino acid residue substitutions are based on the predicted amino acid sequences obtained by CLUSTAL W alignments of the lack, tsa, lmsti1,
and leif genes from different species of Leishmania. *, predicted amino acids between positions 158 and 220 of sti1 (for details, see Fig. 1).
b The L. (V.) braziliensis lack and leif genes had already been cloned from different parasite strains. NA, gene sequence not available in GenBank.
VOL. 14, 2007 IMMUNIZATION AGAINST LEISHMANIA (V.) BRAZILIENSIS 1175
motifs described previously as characteristic of the DEAD box
family of RNA helicases (29).
Expression of lack-, tsa-, Lbsti-, and leif-coding ORFs during
the L. (V.) braziliensis life cycle. In order to characterize the
transcripts expressed by the different forms of L. (V.) brazilien-
sis, Northern blotting was performed with total RNA that was
hybridized with the coding ORFs of lack, tsa, Lbsti, leif, and
-tubulin (positive control) (12). As shown in Fig. 2, both life
stages of L. (V.) braziliensis and promastigotes of L. (L.) major
(positive control) displayed bands corresponding to transcript
sizes of approximately 1.5 to 2.0 kb (lack, Fig. 2A), 2.0 kb (tsa,
Fig. 2B), 2.5 to 3.0 kb (leif, Fig. 2C), and 2.5 kb (lbsti1, Fig. 2D).
The hybridization was specific for the parasite RNA, since the
RNA from uninfected macrophages failed to hybridize with
lack, tsa, Lbsti, and leif probes. All RNA samples from the
different forms of the parasite and control uninfected macro-
phages hybridized with -tubulin probe used as positive con-
trols (Fig. 2E).
IIA for detection of LACK, TSA, LbSTI1, and LeIF antigens
on amastigote and promastigote forms of L. (V.) braziliensis.
The coding ORFs of lack, tsa, Lbsti, or leif were subcloned in
the pET22() vector, and the recombinant protein was ex-
pressed and purified as described in Materials and Methods.
Figure 3 shows the SDS-PAGE analyses of the purified recom-
binant proteins. Each protein migrated as a single band (except
the LeIF protein) and according to the expected molecular
mass. To determine whether these four antigens were in fact
expressed by promastigotes and amastigotes of L. (V.) bra-
ziliensis, we generated specific polyclonal antibodies to the
different antigens. By IIA, it was possible to determine that
promastigote forms of L. (V.) braziliensis (MHOM/BR/1975/
M2903 strain) were specifically recognized by antibodies from
mice immunized with each recombinant protein (Fig. 4). An-
tibody recognition was specific to the recombinant proteins
because sera from mice immunized with CFA or IFA alone
failed to react with promastigotes (Fig. 4J). Immunoblot anal-
ysis of the parasite extract confirmed that each antigen was
recognized by the specific immune sera raised by mouse re-
combinant protein immunization (Fig. 4M).
Subsequently, we performed IIA analysis with macrophages
infected with L. (V.) braziliensis (MHOM/BR/1975/M2903
strain) as substrates. Amastigotes were specifically recognized
by antibodies from mice immunized with each recombinant
FIG. 1. Comparison of the predicted amino acids 158 to 220 of the sti1 genes from L. (V.) braziliensis, L. (L.) major, or L. (L.) donovani. Alignments
were obtained by the CLUSTAL W method. Residues that are different in the predicted amino acid sequences of L. (V.) braziliensis are boxed with a
black background. Positions with substitutions between the L. (L.) major and L. (L.) donovani are boxed with gray background.
FIG. 2. RNA expression of lack, tsa, leif, or Lbsti1 genes from L. (V.) braziliensis. Northern blot analysis was performed with lack (A), tsa (B),
leif (C), lbsti (D), and -tubulin (E) (12) ORFs as probes. Each lane contains 10 g of total RNA of promastigotes of L. (L.) major (lane 1, positive
control), promastigotes (lane 2) or amastigotes (lane 3) of L. (V.) braziliensis, or uninfected cultured macrophages (lane 4, negative control)/lane.
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protein (Fig. 5). Antibody recognition was specific to the re-
combinant proteins because sera from mice immunized with
CFA alone failed to react with control macrophages (data not
shown) and infected macrophages (Fig. 5R). In order to visu-
alize the amastigotes clearly, these infected macrophages were
costained with sera from humans infected with L. (V.) bra-
ziliensis.
Immune response generated by immunization with recom-
binant antigens from L. (V.) braziliensis. To characterize the
immune response generated by different immunization strate-
gies using the L. (V.) braziliensis antigens, we immunized mice
with plasmids encoding each antigen or the respective recom-
binant proteins. Recombinant proteins were administered in
the presence of CpG ODN 1826 and alum.
In BALB/c mice immunized with each plasmid DNA indi-
vidually or a combination of all plasmids we only observed
FIG. 3. SDS-PAGE analyses of purified bacterial recombinant pro-
teins from L. (V.) braziliensis. Proteins were submitted to SDS-PAGE
under reducing conditions and stained with Coomassie blue. MW,
molecular mass standard. The amount of each recombinant protein
was approximately 600 ng per lane.
FIG. 4. IIA recognition of promastigotes of L. (V.) braziliensis by immune sera from mice immunized with recombinant proteins. Parasites were
incubated with a pool of sera derived from mice immunized with the respective recombinant protein and imaged under Nomarski differential
interference contrast (A, C, E, G, I, and K) or fluorescence (B, D, F, H, J, and L). Magnification, 1,000. Control sera was obtained from mice
immunized with CFA or IFA alone. (M) Immunoblot of promastigote extract (30 g of protein/lane) stained with a pool of sera from BALB/c mice
immunized with the different recombinant proteins. Lanes: 1, LACK-immunized mice; 2, TSA-immunized mice; 3, LeIF-immunized mice; 4,
LbSTI1-immunized mice; 5, mice immunized with all four antigens.
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specific antibodies to the LbSTI1 antigen. This immune re-
sponse was present in mice immunized with the lbsti1 gene or
all of the genes together (Fig. 6A). In both cases, a predomi-
nance of IgG2a over IgG1 was observed. The ratios of IgG1 to
IgG2a were 0.93 and 0.76 in mice immunized with the lbsti1
gene or all genes together, respectively. These immune sera
were also tested by IIA. We observed that sera from DNA
vaccinated mice failed to recognize promastigotes (data not
shown).
In BALB/c mice immunized with each recombinant protein
individually or a combination of all of them we detected high
titers of antibodies to the different antigens in each group of
immunized mice (Fig. 6B). The ratios of IgG1 to IgG2a for
each mouse group were as follows: 1.3, LACK; 0.92, TSA; 1.18,
LeIf; 1.45, LbSTI1; and 1.48, all antigens. These immune sera
were also tested by IIA. We observed that sera from recombi-
nant protein-vaccinated mice strongly recognized promasti-
gotes (data not shown). The antibody production was specific
since the injection of pcDNA3 or adjuvant alone failed to elicit
specific antibodies to any Leishmania antigen.
We also measured the IFN-	 produced by spleen cells from
mice immunized with the different recombinant antigens as
plasmid DNA or recombinant proteins. Upon in vitro restimu-
lation with recombinant proteins, we detected antigen-specific
IFN-	 production in cultured spleen cells from most groups of
mice immunized with the distinct antigen either as plasmid
DNA or recombinant protein (Fig. 7B and D). However, after
antigenic stimulation in vitro, spleen cells from mice immu-
nized with the tsa gene or the LbSTI1 recombinant protein
failed to produce levels of IFN-	 that were significantly differ-
ent from those of control cultures (Fig. 7A and C). The anti-
gen-specific IFN-	 production was dependent on the immuni-
zation with the Leishmania antigens since spleen cells from
control mice immunized with pcDNA3 (Fig. 7A) or CpG ODN
1826 and alum (Fig. 7C) failed to secrete this cytokine in the
presence of the different recombinant antigens.
Immunization with L. (V.) braziliensis antigens failed to
elicit protective immunity against experimental infection in
BALB/c mice. To determine whether immunization with any of
these genes or antigens alone or in combination could elicit
protective immunity against experimental infection, BALB/c
mice were immunized twice with plasmid DNA, followed by
one or two doses of recombinant protein in the presence CpG
ODN 1826 and alum. The immune sera of these mice were
tested by IIA. We observed that sera from vaccinated mice
recognized promastigotes (data not shown).
Two weeks after the last dose, mice were then challenged
with infective promastigotes of L. (V.) braziliensis (MHOM/
BR/01/BA788 strain) in the dermis in both ears. We monitored
the nodule formation for 9 or 10 weeks. We did not observe a
FIG. 5. IIA recognition of amastigotes of L. (V.) braziliensis by immune sera from mice immunized with recombinant proteins. Mouse bone
marrow macrophages infected with amastigotes of L. (V.) braziliensis were incubated with mouse antibodies specific to LACK (A to D), TSA (E
to H), LeiF (I to L), or LbSTI1 (M to P). Additional slides were stained with negative (Q to T) or positive (U to X) control sera. All slides were
costained with a pool of sera from humans infected with ML and with DAPI. Secondary antibodies to mouse IgG or human IgG were labeled with
rhodamine (red fluorescence) or anti-FITC (green fluorescence), respectively. The images were captured by using Nomarski differential inter-
ference contrast (A, E, I, M, Q, and U) or fluorescence for rhodamine (B, F, J, N, R, and V) or FITC (C, G, R, O, S, and W). Fluorescence images
for rhodamine, FITC, and DAPI (blue) were merged in panels D, H, L, P, T, and X. Magnification, 1,000. Negative control sera were obtained
from mice immunized with CFA or IFA alone.
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protective immune response as expressed by a significant re-
duction in the lesion size in immunized mice compared to the
control group that received control plasmid followed by adju-
vant (Fig. 8).
DISCUSSION
The present study was designed to evaluate the vaccination
potential of four L. (V.) braziliensis genes or antigens (LACK,
LbSTI1, LeIF, and TSA) in a newly developed experimental
model of infection (20). These four genes or antigens were
selected based on previous successful vaccination against ex-
perimental infection in BALB/c mice with L. (L.) major (re-
viewed in references 9 and 21). Initially, we cloned these four
genes from genomic DNA of L. (V.) braziliensis. Deduced
amino acid sequence analysis of each one of these genes
showed that they are quite conserved. Nevertheless, lbsti1 ORF
presented a clear polymorphism compared to L. (L.) major and
L. (L.) donovani ORFs in the region spanning amino acids 158
to 220 (Fig. 1). The significance of this polymorphism should
be further evaluated in the future.
Subsequently, we characterized whether these genes or an-
tigens were expressed on the different forms of L. (V.) bra-
ziliensis. We provided evidence that all four genes or antigens
were expressed on promastigote and amastigote forms. Based
on the fact that these antigens were expressed in the intracel-
lular forms of L. (V.) braziliensis, we performed immunization
studies with either recombinant plasmids or bacterial recom-
binant proteins. We found that plasmid immunization failed to
induce an antibody response except after immunization with
the gene lbsti1. Nevertheless, IFN-	-producing spleen cells
were generated after individual immunization with three of the
FIG. 6. Antibody immune response of mice immunized with eu-
karyotic expression plasmids or bacterial recombinant proteins ex-
pressing L. (V.) braziliensis antigens. (A) BALB/c mice (n 
 6) were
immunized with three doses of plasmids containing the indicated genes
or pcDNA3 (control empty plasmid). Two weeks after the last immu-
nization, blood samples were collected, and the sera were assayed by
ELISA for the presence of antibodies to the respective recombinant
proteins. Mice immunized with all plasmids were tested against the
LbSTI1 recombinant protein only. (B) BALB/c mice (n 
 7) were
immunized with three doses of the indicated recombinant protein or
adjuvant only (CpG ODN 1826 plus alum). Two weeks after the last
immunization, blood samples were collected, and the sera were as-
sayed by ELISA for the presence of antibodies to the respective re-
combinant proteins. Mice immunized with all proteins were tested in
wells coated with all recombinant proteins. The results are presented
as means  the SD of reciprocal antibody dilutions (log10) providing
an optical density at 492 nm greater than 0.1.
FIG. 7. IFN-	 secretion by spleen cells from BALB/c mice immu-
nized with different plasmids or recombinant antigens of L. (V.) bra-
ziliensis upon in vitro restimulation with the respective recombinant
proteins. BALB/c mice were immunized with three doses of plasmids
containing the indicated genes (B) or pcDNA3 (A). Alternatively,
BALB/c mice were immunized with three doses of the indicated re-
combinant proteins (D) or alum plus CpG ODN (C). Two weeks after
the last immunizing dose, spleen cells of each individual mouse were
stimulated in vitro with 10 g of recombinant protein/ml. The concen-
tration of IFN-	 was estimated in cell culture supernatants. The results
are expressed as average of three mice  the SD. This experiment was
reproduced twice with identical results. Asterisks denote statistically
significant differences from values in the supernatants of spleen cells
cultured in the absence of the recombinant protein (P  0.05, one-way
analysis of variance).
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four plasmids used containing the genes lack, leif, and lbsti1 or
all plasmids together.
Immunization of BALB/c mice with recombinant proteins
admixed with the adjuvants CpG ODN 1826 and alum induced
potent antibody immune responses. IFN-	-producing spleen
cells were also generated in mice immunized individually with
three of the antigens (LACK, TSA, and LeIF) or all of the
antigens together. Finally, we immunized mice with a com-
bined protocol consisting of priming with plasmid DNA fol-
lowed by booster injections with recombinant proteins. This
protocol was based on our previous study showing that the
heterologous prime-boost immunization induced high levels of
cell-mediated immunity against a Trypanosoma cruzi antigen
(33). In spite of the immune responses induced by a heterol-
ogous prime-boost immunization with these genes or antigens
after an i.d. challenge of immunized BALB/c mice with L. (V.)
braziliensis infective promastigotes, we were unable to observe
any significant reduction in the lesion size up to 10 weeks after
challenge.
In addition to the BALB/c mouse model, we also immunized
C57BL/6 mice with the different plasmids individually or all
together. Similarly, we were unable to detect significant reduc-
tion of the primary lesion size after a subcutaneous footpad
challenge with L. (V.) braziliensis (data not shown).
Thus far, we were unable to detect any reduction in the
lesion sizes of vaccinated challenged animals. However, it will
be important to establish more sensitive methods to determine
the number of L. (V.) braziliensis in the lesion using real-time
PCR. In general, our results contrast with previous findings
from studies performed with L. (L.) major. Using distinct
mouse models of infection, significant reduction in the primary
lesion sizes were observed in mice vaccinated with these genes
or antigens either as recombinant plasmids or proteins. The
reduction in the lesion size was observed after a subcutaneous
footpad challenge with large doses of promastigotes (5, 6, 10,
14, 15, and 30). Also, significant reductions in the lesion size
were reported after i.d. challenge in the mouse ear (17, 18, 22).
These results established unequivocally the protective poten-
tial of these recombinant genes or antigens provided as plas-
mid DNA or recombinant proteins.
Using our plasmid containing the lack gene of L. (V.) bra-
ziliensis, we confirmed that immunization of BALB/c mice elic-
ited protective immunity capable of significantly reduce the
lesion size after a footpad challenge with L. (L.) major (data
not shown). Similarly, Melby et al. (16) showed that vaccina-
tion with the lack gene induced potent immune responses but
failed to provide protective immunity against an experimental
challenge with L. (L.) donovani (visceral leishmaniasis). Based
on that finding, we considered that the biological differences
between L. (L.) major, L. (V.) braziliensis, and L. (L.) donovani
may account for the inability to elicit protective immune re-
sponses against a challenge with the last two.
In summary, although our results are essentially negative in
terms of the induction of protective immunity, we consider it
important because it suggests that the research efforts aimed at
the development of a recombinant vaccine against L. (V.) bra-
ziliensis should be redirected toward different parasite antigens
or different vaccination strategies.
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